Featured Poster: Eyebrows and Eyelashes Regrowth Across Different SALT Response Thresholds in Patients with Alopecia Areata: Outcomes from the BRAVE AA Clinical Program
In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Senna and colleagues analyze eyebrow and eyelash regrowth in a 52-week extension study of baricitinib
By Dermsquared Editorial Team | June 16, 2023
Baricitinib is an oral JAK1/JAK2 inhibitor that demonstrated efficacy in achieving Severity of Alopecia Tool (SALT) score ≤20 at week 36 in the phase 2/3 trial BRAVE-AA1 and the phase 3 trial BRAVE-AA2 for the treatment of severe alopecia areata (AA).
This poster presents data from a 52-week extension study to evaluate whether patients with AA treated with baricitinib who had not achieved SALT score ≤20 achieved meaningful improvements in eyebrow or eyelash loss.
At week 52, all response subgroups achieved meaningful improvement in eyebrow and eyelash regrowth. The highest response rates were in the subgroup that achieved SALT score ≤20, but about half of the patients with partial scalp response and 15% to 20% of those with no scalp response also experienced meaningful improvement in eyebrow and eyelash regrowth.